Search
Eteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigationalEteplirsen was the first treatment for DMD approved by the FDA.[A244925] … [L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications.
Magnesium cation
go.drugbank.com/drugs/DB01378ApprovedInvestigationalNutraceuticalWithdrawnMilk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn.
Mixtures: KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 30 ADET, KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 40 ADETLusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan).
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalFrom this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. … Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
Lerodalcibep
go.drugbank.com/drugs/DB19071ApprovedInvestigational[L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia
Follitropin
go.drugbank.com/drugs/DB00066ApprovedInvestigationalHowever, these small differences do not affect the bioactivity compared to natural FSH. … Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).
Mixtures: PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 3 ADETProducts: Puregon (600 Iu), GONAL - F 75 IUProtein S human
go.drugbank.com/drugs/DB13149ApprovedInvestigationalProtein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.
Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigational[L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in … [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals.
Saxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Nitrofural
go.drugbank.com/drugs/DB00336ApprovedVet approvedWithdrawnExcept for topical drug products formulated for dermatologic application, the FDA withdrew its approval for the use of drug products containing nitrofurazone.[L43942]